AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25057165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deintensified treatment regimens for HPV-positive LA OPC
Number of subjects: 0
Study 25057165 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-targeted strategies (vaccines)
Number of subjects: 0
Study 25057165 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive recurrent/metastatic (RM) disease
Number of subjects: 0
Study 25057177 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. weekly added to rituximab (375 mg/m2 i.v. day 1) and cladribine (5 mg/m2/day i.v. days 1-5 of a 28-day cycle)
Number of subjects: 17
Study 25057177 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. weekly added to rituximab and cladribine
Number of subjects: 17
Study 25057265 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 274
Study 25057265 — intervention group
Group type: COMPARATOR
Intervention: Nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs)
Number of subjects: 274
Study 25057276 — intervention group
Group type: EXPERIMENTAL
Intervention: pterostilbene 125 mg twice daily
Number of subjects: 80
Study 25057276 — intervention group
Group type: EXPERIMENTAL
Intervention: pterostilbene 50 mg twice daily
Number of subjects: 80
Study 25057276 — intervention group
Group type: EXPERIMENTAL
Intervention: pterostilbene 50 mg + grape extract (GE) 100 mg twice daily
Number of subjects: 80
Study 25057276 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose pterostilbene
Number of subjects: 80
Study 25057276 — intervention group
Group type: EXPERIMENTAL
Intervention: pterostilbene
Number of subjects: 80
Study 25057276 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 25058217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) with alemtuzumab (1 mg/kg), total-body irradiation (300 cGy), sirolimus, and filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10(6) cells/kg)
Number of subjects: 30
Study 25058217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic HSCT
Number of subjects: 30
Study 25058267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal-serum lactate ratio greater than 4.5
Number of subjects: 88
Study 25058267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lactate value greater than 9.1 mmol/L
Number of subjects: 88
Study 25058615 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17A production by CD146+ T cells in psoriatic blood and lesions
Number of subjects: 0
Study 25059766 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative magnetic resonance imaging (MRI)
Number of subjects: 199
Study 25060819 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide (FeNO) measurements
Number of subjects: 50
Study 25060819 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without FeNO
Number of subjects: 50
Study 25060819 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of FeNO in addition to standard of care
Number of subjects: 50
Study 25061140 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes patients
Number of subjects: 194
Study 25061140 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 194
Study 25061149 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine for diabetes care
Number of subjects: 0
Study 25061149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25061868 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal safe tumor resection
Number of subjects: 97
Study 25061868 — intervention group
Group type: COMPARATOR
Intervention: Large residual tumors (> 3 cm³)
Number of subjects: 97
Study 25061868 — intervention group
Group type: COMPARATOR
Intervention: Large residual tumors
Number of subjects: 97
Study 25061868 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster regrowth rate
Number of subjects: 97
Study 25062507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 30/30 mg twice daily
Number of subjects: 553
Study 25062744 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL3-C
Number of subjects: 4932
Study 25062744 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL2-C
Number of subjects: 4932
Study 25062744 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 4932
Study 25062770 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 0.1 or 0.2 mg/kg three times weekly for 2 weeks, Panobinostat 10, 20, or 30 mg every 96 h, Temozolomide 150 mg/m(2)/day on days 9-13 (increased to 200 mg/m(2)/day in cycle 2 if no neutropenia or thrombocytopenia)
Number of subjects: 20
Study 25062770 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance protocol with weekly panobinostat and thrice-weekly decitabine until tumor progression, unacceptable toxicity, or withdrawal of consent
Number of subjects: 20
Study 25063332 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2
Number of subjects: 0
Study 25063332 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel imaging techniques and biomarkers
Number of subjects: 0
Study 25063541 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnostic criteria
Number of subjects: 0
Study 25063541 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study 25063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and clinical outcomes testing
Number of subjects: 0
Study 25063544 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin 33,000 IU intravenously on 3 consecutive days
Number of subjects: 0
Study 25064025 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (400-1600 IU/d)
Number of subjects: 132
Study 25064094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (1200 mg/day) for 24 months
Number of subjects: 28
Study 25064285 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program for 12 weeks
Number of subjects: 134
Study 25065380 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-focused ultrasound with visualization (MFU-V)
Number of subjects: 30
Study 25065582 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal junctional tourniquet (JT)
Number of subjects: 10
Study 25066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational engagement at baseline
Number of subjects: 108
Study 25066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation for day centre activities
Number of subjects: 108
Study 25066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Not preferring work before attending the day centre
Number of subjects: 108
Study 25066363 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon® Micro (5000 lipase units/spoon)
Number of subjects: 40
Study 25066554 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 15000
Study 25066554 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of anticoagulation surrounding bleeding events
Number of subjects: 15000
Study 25067982 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus probenecid
Number of subjects: 12
Study 25067982 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan alone
Number of subjects: 12
Study 25067985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cactus fiber (2 tablets thrice daily with main meals)
Number of subjects: 20
Study 25067985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets thrice daily with main meals)
Number of subjects: 20
Study 25069627 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids and/or acetaminophen (oral oxycodone and/or acetaminophen)
Number of subjects: 200
Study 25069627 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (total daily consumption)
Number of subjects: 200
Study 25069627 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic administration methods
Number of subjects: 200
Study 25069627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, pruritus, altered level of consciousness
Number of subjects: 200
Study 25070153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicorandil (15 mg/d, nicorandil group)
Number of subjects: 100
Study 25070153 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 100
Study 25070153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicorandil
Number of subjects: 100
Study 25071871 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental skills assessment in classic RTT
Number of subjects: 638
Study 25071871 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental skills assessment in atypical RTT
Number of subjects: 638
Study 25071871 — intervention group
Group type: COMPARATOR
Intervention: Comparison of skills acquisition between classic RTT and atypical RTT
Number of subjects: 638
Study 25071871 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation for Motor Behavioral Assessment
Number of subjects: 638
Study 25071871 — intervention group
Group type: EXPERIMENTAL
Intervention: General linear model for age of acquisition or loss of developmental skill
Number of subjects: 638
Study 25072443 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% saline with 6% dextran 70
Number of subjects: 2061
Study 25072443 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% saline
Number of subjects: 2061
Study 25072443 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 2061
Study 25072443 — intervention group
Group type: COMPARATOR
Intervention: Shock cohort
Number of subjects: 2061
Study 25072443 — intervention group
Group type: COMPARATOR
Intervention: TBI cohort
Number of subjects: 2061
Study 25072443 — intervention group
Group type: COMPARATOR
Intervention: Cohort with both shock and TBI
Number of subjects: 2061
Study 25072443 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2061
Study 25072733 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of cyp51 A key mutations using PCR assays
Number of subjects: 155
Study 25072733 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of azole resistance in clinical isolates
Number of subjects: 155
Study 25072733 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PCR assay for cyp51 A 46 bp tandem repeat (TR46)
Number of subjects: 155
Study 25072780 — intervention group
Group type: EXPERIMENTAL
Intervention: Y(90) ibritumomab tiuxetan and BEAM regimen followed by autologous stem cell transplantation (ASCT)
Number of subjects: 75
Study 25072816 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 441
Study 25072816 — intervention group
Group type: EXPERIMENTAL
Intervention: s-cTnI
Number of subjects: 441
Study 25073894 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 30
Study 25074036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (800-1,000 mg/m² on days 1, 8, and 15, then every 3-4 weeks)
Number of subjects: 33
Study 25074036 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40-80 mg/m²/day on days 1-28, then every 3-6 weeks)
Number of subjects: 33
Study 25074070 — intervention group
Group type: COMPARATOR
Intervention: Tree nuts
Number of subjects: 2226
Study 25074070 — intervention group
Group type: COMPARATOR
Intervention: Control diet interventions
Number of subjects: 2226
Study 25074375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES neighborhoods
Number of subjects: 1557
Study 25074375 — intervention group
Group type: COMPARATOR
Intervention: High SES neighborhoods
Number of subjects: 1557
Study 25074459 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib + Cetuximab
Number of subjects: 126
Study 25074504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 514
Study 25074699 — intervention group
Group type: EXPERIMENTAL
Intervention: Set 1: Ѳ(Tp|Tref) >42°; Ѳ(Tinit|Tterm) >30°; STJ depression in V6; rate-adjusted QTp interval (QTpa)
Number of subjects: 52994
Study 25074699 — intervention group
Group type: EXPERIMENTAL
Intervention: Set 2: TaVR amplitude >-100 μV; TV1 >175 μV; QRS duration >100 ms
Number of subjects: 52994
Study 25075006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 1734
Study 25075006 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1734
Study 25075006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux with unfractionated heparin (UFH)
Number of subjects: 1734
Study 25075128 — intervention group
Group type: EXPERIMENTAL
Intervention: Afuresertib (125 mg per day, maximum tolerated dose)
Number of subjects: 73
Study 25075128 — intervention group
Group type: EXPERIMENTAL
Intervention: Afuresertib (doses ranging from 25 to 150 mg per day)
Number of subjects: 73
Study 25075128 — intervention group
Group type: EXPERIMENTAL
Intervention: Afuresertib (doses > 75 mg)
Number of subjects: 73
Study 25075804 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 341
Study 25075833 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 (30 mg per day for 3 days)
Number of subjects: 21
Study 25075833 — intervention group
Group type: COMPARATOR
Intervention: Oral artesunate (not specified dosage or duration)
Number of subjects: 21
Study 25075853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 0
Study 25075853 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25075930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic motivation
Number of subjects: 431
Study 25075930 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in motivation during the 6-month follow-up
Number of subjects: 431
Study 25076364 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL)
Number of subjects: 36
Study 25076495 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets emphasizing tree nuts (median dose of 56 g/d)
Number of subjects: 450
Study 25076495 — intervention group
Group type: COMPARATOR
Intervention: Control diets (isocaloric diets without tree nuts)
Number of subjects: 450
Study 25077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine sulfate syrup (initially 0.5 mg twice daily, titrated based on weekly assessments)
Number of subjects: 44
Study 25077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine sulfate syrup
Number of subjects: 44
Study 25077107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient vitamin D levels (≥ 75 nmol/L)
Number of subjects: 173
Study 25077107 — intervention group
Group type: COMPARATOR
Intervention: Insufficient vitamin D levels (< 75 nmol/L)
Number of subjects: 173
Study 25077537 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope reflectance imaging
Number of subjects: 18
Study 25077537 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics infrared flood imaging
Number of subjects: 18
Study 25077901 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL1-apoB
Number of subjects: 62
Study 25077901 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fat
Number of subjects: 62
Study 25077901 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL1-triglycerides (TGs) indirect FCR
Number of subjects: 62
Study 25077901 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL1-TG production rate
Number of subjects: 62
Study 25077901 — intervention group
Group type: EXPERIMENTAL
Intervention: apoA-II FCR
Number of subjects: 62
Study 25078269 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56+ lung lymphocytes
Number of subjects: 60
Study 25078269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung NK cells (CD56+ CD3-) and CD56+ T cells (CD56+ CD3+)
Number of subjects: 60
Study 25078269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous lung epithelial cells
Number of subjects: 60
Study 25078269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung CD56+ cells
Number of subjects: 60
Study 25078269 — intervention group
Group type: COMPARATOR
Intervention: CD4+ or CD8+ conventional lung T cells
Number of subjects: 60
Study 25079400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen with oral hygiene products and non-surgical therapy
Number of subjects: 120
Study 25079400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen
Number of subjects: 120
Study 25079603 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1 isolates from patients with slow disease progression
Number of subjects: 107
Study 25079603 — intervention group
Group type: COMPARATOR
Intervention: HCV genotype 1 isolates from patients with rapid disease progression
Number of subjects: 107
Study 25079603 — intervention group
Group type: COMPARATOR
Intervention: General assessment of viral genetic variation and HCC
Number of subjects: 107
Study 25079603 — intervention group
Group type: COMPARATOR
Intervention: Assessment of amino acid distributions and selection pressures
Number of subjects: 107
Study 25079662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minorities (African Americans, Hispanics, Chinese Americans)
Number of subjects: 1055
Study 25079662 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status and modifiable diabetes-specific risk/protective factors (healthcare access/utilization, subjective diabetes burden, social support/burden)
Number of subjects: 1055
Study 25079662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for risk/protective factors
Number of subjects: 1055
Study 25079662 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between ethnicity and other correlates of psychological outcomes
Number of subjects: 1055
Study 25080050 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated raised base excess (BE) (≥ 2 mmol/L)
Number of subjects: 71
Study 25080050 — intervention group
Group type: COMPARATOR
Intervention: Established OHS (awake hypercapnia > 6 kPa)
Number of subjects: 71
Study 25080050 — intervention group
Group type: COMPARATOR
Intervention: Normal blood gas measurements and normal acid-base balance
Number of subjects: 71
Study 25080392 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 4987
Study 25080392 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 4987
Study 25080392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4987
Study 25080428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric content by anaesthesiologists
Number of subjects: 32
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 253
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia prevalence
Number of subjects: 253
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (sTfR > 8.5 mg/L)
Number of subjects: 253
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentrations
Number of subjects: 253
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO as an indicator of iron status
Number of subjects: 253
Study 25080540 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO explained variance in hemoglobin
Number of subjects: 253
Study 25080553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 217
Study 25080874 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache Impact Test (HIT-6)
Number of subjects: 1384
Study 25081818 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage
Number of subjects: 39
Study 25081818 — intervention group
Group type: COMPARATOR
Intervention: Problem Solving Therapy (PST)
Number of subjects: 39
Study 25082288 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaphorin-plexin system targeting
Number of subjects: 0
Study 25082342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 2.5mg followed by 5.0mg continuous
Number of subjects: 37
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for BEST1 in BMD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for EFEMP1 in DHRD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for TIMP3 in SFD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for PRPH2 in PD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for ABCA4 in PD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for GUCY2D in CRD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for ABCA4 in CRD patients
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genetic testing results
Number of subjects: 213
Study 25082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective screening for mutations in BEST1, PRPH2, and ABCA4
Number of subjects: 213
Study 25082970 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically right anterior innominate dysfunctions)
Number of subjects: 98
Study 25082970 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically left superior shear)
Number of subjects: 98
Study 25082970 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically left-on-left sacral torsion)
Number of subjects: 98
Study 25082970 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically right anterior innominate rotation dysfunctions)
Number of subjects: 98
Study 25083135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6000
Study 25083135 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6000
Study 25084088 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional MRI-guided deep brain stimulation (DBS) using the ClearPoint system
Number of subjects: 6
Study 25084263 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure
Number of subjects: 0